Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP-002 Gene Therapy in Pediatric Patients With STXBP1 Encephalopathy
NCT06983158Phase 2Terminated
- Sponsor
- Capsida Biotherapeutics
- Start
- Jul 2025
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of CAP-002 in STXBP1 encephalopathy (STXBP1E), sponsored by Capsida Biotherapeutics. Started Jul 2025; status: terminated.
02
Drugs
CAP-002
03
Conditions
STXBP1 encephalopathy (STXBP1E)
Beyond the preview
Go deeper on NCT06983158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06983158.